MedPageToday -- NATIONAL HARBOR, Md. -- Two-thirds of patients with triple-negative breast cancer achieved pathologic complete response (pCR) with neoadjuvant chemotherapy consisting of carboplatin and docetaxel (Taxotere), data from a small clinical study showed.
